Thinly traded Cortexyme (CRTX +27.3%) is up on triple normal volume, albeit on turnover of only 177K shares, ahead of tomorrow’s fireside chat by CEO Casey Lynch at Evercore ISI’s HealthCONx Conference in Boston at 2 pm ET.
The company’s lead candidate is COR388, a brain-penetrating small molecule gingipain inhibitor for the potential treatment of Alzheimer’s disease (AD).
Gingipains are toxic enzymes secreted by a certain bacterium present in 90% of the brains of AD sufferers.
A Phase 2/3 study, GAIN, is in process.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.